Skip to main content

Regeneron Pharmaceuticals EYLEA revenue

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

EYLEA revenue at Regeneron Pharmaceuticals came to $399.7M for the quarter to 30 Sep 2026, down 41.3% from a year earlier.

As Regeneron Pharmaceuticals reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$1.3BDec 2023$1.2BMar 2024$1.2BJun 2024$1.1BSep 2024$1.2BDec 2024$736.0MMar 2025$754.3MJun 2025$680.6MSep 2025$576.9MDec 2025$473.1MMar 2026$412.2MJun 2026$399.7MSep 2026
Regeneron Pharmaceuticals EYLEA revenue, every reported period
Period endingEYLEA revenueChange on a yearFiled
30 Sep 2026$399.7Mdown 41.3%30 Oct 2026
30 Jun 2026$412.2Mdown 45.4%30 Jul 2026
31 Mar 2026$473.1Mdown 35.7%29 Apr 2026
31 Dec 2025$576.9Mdown 51.5%4 Feb 2026
30 Sep 2025$680.6Mdown 40.5%28 Oct 2025
30 Jun 2025$754.3Mdown 38.7%1 Aug 2025
31 Mar 2025$736.0Mdown 38.7%29 Apr 2025
31 Dec 2024$1.2Bdown 11.0%5 Feb 2025
30 Sep 2024$1.1Bdown 21.0%31 Oct 2024
30 Jun 2024$1.2Bdown 18.0%1 Aug 2024
31 Mar 2024$1.2Bdown 16.2%2 May 2024
31 Dec 2023$1.3Bdown 10.6%5 Feb 2024
30 Sep 2023$1.4Bdown 11.1%2 Nov 2023
30 Jun 2023$1.5Bdown 7.5%3 Aug 2023
31 Mar 2023$1.4Bdown 5.5%4 May 2023
31 Dec 2022$1.5Bdown 3.3%6 Feb 2023
30 Sep 2022$1.6Bup 10.6%3 Nov 2022
30 Jun 2022$1.6Bup 13.8%3 Aug 2022
31 Mar 2022$1.5Bup 12.7%4 May 2022
31 Dec 2021$1.5Bup 15.2%7 Feb 2022
30 Sep 2021$1.5Bup 11.8%4 Nov 2021
30 Jun 2021$1.4Bup 27.9%5 Aug 2021
31 Mar 2021$1.3Bup 14.9%6 May 2021
31 Dec 2020$1.3Bup 9.9%8 Feb 2021
30 Sep 2020$1.3Bup 11.0%5 Nov 2020
30 Jun 2020$1.1Bdown 4.0%5 Aug 2020
31 Mar 2020$1.2Bup 9.1%5 May 2020
31 Dec 2019$1.2Bup 13.3%7 Feb 2020
30 Sep 2019$1.2Bup 16.2%5 Nov 2019
30 Jun 2019$1.2Bup 17.0%6 Aug 2019
31 Mar 2019$1.1Bup 9.2%7 May 2019
31 Dec 2018$1.1B—7 Feb 2019
30 Sep 2018$1.0Bup 7.2%6 Nov 2018
30 Jun 2018$992.0Mup 7.9%2 Aug 2018
31 Mar 2018$984.0M—3 May 2018
30 Sep 2017$953.3M—8 Nov 2017
30 Jun 2017$919.5M—3 Aug 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Regeneron Pharmaceuticals: Collaboration revenue · Net product sales · Libtayo revenue · Lynozyfic revenue · EYLEA HD And EYLEA revenue · EYLEA HD revenue · Praluent revenue · Evkeeza revenue · financial statements

Every KPI and segment of REGN, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.